Regulatory update – GSK announces European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma

Issued: Thursday 7 February 2013, London UK – LSE Announcement

GlaxoSmithKline (GSK) plc today announced submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for trametinib (MEK) as monotherapy and in combination with dabrafenib (BRAF) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has granted GSK’s request for accelerated assessment of this application.

The application includes data from a randomised, Phase III study of trametinib monotherapy compared to dacarbazine or paclitaxel monotherapy in patients with BRAF V600 mutation positive metastatic melanoma, as well as data from a randomised Phase I/II study comparing dabrafenib monotherapy to combination therapy with dabrafenib and trametinib in patients with BRAF V600 mutation positive metastatic melanoma

"We initiated a randomised study very early in the development programme to test whether the novel-novel combination could circumvent resistance to single agent anti-BRAF therapy and are encouraged by the results from this Phase I/II trial.” said Dr Rafael Amado, Head of Oncology R&D. “We are planning further regulatory submissions based on these data, in the US and other countries in the coming months.”  

An application that has been granted accelerated assessment will have a maximum review time of 150 days. However, at any time during the assessment CHMP may decide to continue the assessment under the standard centralised procedure assessment timelines of 210 days or GSK may submit a request for a change to a standard assessment procedure.

The ongoing Phase III development programme for the combination in BRAF V600 mutation positive melanoma comprises three randomised trials: two trials in the metastatic setting (NCT01584648 and NCT01597908) and one trial in the adjuvant setting (NCT01682083). In August 2012, GSK announced regulatory submissions for dabrafenib monotherapy as a treatment for BRAF V600 metastatic melanoma in the EU and US as well as a US submission for trametinib monotherapy as a treatment for  BRAF V600 metastatic melanoma. Trametinib and dabrafenib are investigational medicines and their use as monotherapy or combination therapy is not approved anywhere in the world.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

GlaxoSmithKline Enquiries:

 

 

 

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

 

Sarah Spencer

+44 (0) 20 8047 5502

(London)

 

David Daley

+44 (0) 20 8047 5502

(London)

 

Catherine Hartley

+44 (0) 20 8047 5502

(London)

 

Alex Harrison

+44 (0) 20 8047 5502

(London)

 

 

 

 

US Media enquiries:

Stephen Rea

+1 215 751 4394

(Philadelphia)

 

Kevin Colgan

+1 919 483 2933

(North Carolina)

 

Melinda Stubbee

+1 919 483 2510

(North Carolina)

 

Mary Anne Rhyne

+1 919 483 0492

(North Carolina)

 

Sarah Alspach

+1 202 715 1048

(Washington, DC)

 

Jennifer Armstrong

+1 215 751 5664

(Philadelphia)

 

 

 

 

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

 

Lucy Budd

+44 (0) 20 8047 2248

(London)

 

Tom Curry

+ 1 215 751 5419

(Philadelphia)

 

Gary Davies

+ 44 (0) 20 8047 5503

(London)

 

James Dodwell

+ 44 (0) 20 8047 2406

(London)

 

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

 

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.